GALT - Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24 2023 | Benzinga
NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023.
Dr. Pol F. Boudes, Galectin Therapeutics' Chief Medical Officer, will deliver a corporate presentation on Tuesday, October 24, 2023 at 11:30 AM ET.
A live webcast of the discussion will be available at this link as well as through the investor relations section of the Company's website at www.galectintherapeutics.com.
About Belapectin
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH when it has progressed to the liver cirrhosis stage as well as advanced cancers. Galectin-3 is produced by activated macrophages, a key inflammatory cell, and plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart, as well as in the cancerous tumor microenvironment. Belapectin binds to galectin-3 and disrupts its function. Belapectin, because of its unique structure, is also captured by activated macrophages and exerts its activity directly at the source of galectin-3 production. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis ...